Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ZLAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ZLAB

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Zai Lab Ltd

ZLAB
Current price
35.66 USD +0.66 USD (+1.89%)
Last closed 34.94 USD
ISIN US98887Q1040
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 4 049 936 896 USD
Yield for 12 month +109.15 %
1Y
3Y
5Y
10Y
15Y
ZLAB
21.11.2021 - 28.11.2021

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is based in Shanghai, China. Address: Jinchuang Plaza, Shanghai, China, 201210

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

54.36 USD

P/E Ratio

Dividend Yield

Financials ZLAB

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ZLAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+398 988 000 USD

Last Year

+266 719 000 USD

Current Quarter

+106 487 000 USD

Last Quarter

+109 070 000 USD

Current Year

+251 128 000 USD

Last Year

+170 903 000 USD

Current Quarter

+67 840 000 USD

Last Quarter

+66 979 000 USD
EBITDA -255 816 992 USD
Operating Margin TTM -52.88 %
Price to Earnings
Return On Assets TTM -15.50 %
PEG Ratio
Return On Equity TTM -32.05 %
Wall Street Target Price 54.36 USD
Revenue TTM 418 326 016 USD
Book Value 7.48 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 22.20 %
Dividend Yield
Gross Profit TTM 24 850 000 USD
Earnings per share -2.50 USD
Diluted Eps TTM -2.50 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -60.26 %

Stock Valuation ZLAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 8.33
Price Sales TTM 9.68
Enterprise Value EBITDA -2.35
Price Book MRQ 4.96

Technical Indicators ZLAB

For 52 Weeks

16.01 USD 44.34 USD
50 Day MA 33.69 USD
Shares Short Prior Month 5 109 230
200 Day MA 30.03 USD
Short Ratio 4.27
Shares Short 4 388 732
Short Percent 4.55 %